Krensavage Asset Management is an investment fund managing more than $218 million ran by Paul Paolino. There are currently 13 companies in Mr. Paolino’s portfolio. The largest investments include Exelixis Inc and United Therapeutics Corp, together worth $75.3 million.
As of 8th August 2024, Krensavage Asset Management’s top holding is 1,677,393 shares of Exelixis Inc currently worth over $37.7 million and making up 17.3% of the portfolio value.
Relative to the number of outstanding shares of Exelixis Inc, Krensavage Asset Management owns more than approximately 0.1% of the company.
In addition, the fund holds 118,208 shares of United Therapeutics Corp worth $37.7 million, whose value grew 50.8% in the past six months.
The third-largest holding is Biogen Inc worth $28.7 million and the next is Taro Pharmaceutical Indus worth $28 million, with 650,089 shares owned.
Currently, Krensavage Asset Management's portfolio is worth at least $218 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Krensavage Asset Management office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Paul Paolino serves as the Chief Financial Officer/Chief Compliance Officer at Krensavage Asset Management.
In the most recent 13F filing, Krensavage Asset Management revealed that it had opened a new position in
Jazz Pharmaceuticals plc and bought 109,076 shares worth $11.6 million.
This means they effectively own approximately 0.1% of the company.
Jazz Pharmaceuticals plc makes up
6.8%
of the fund's Health Care sector allocation and has decreased its share price by 20.2% in the past year.
The investment fund also strengthened its position in Taro Pharmaceutical Indus by buying
7,009 additional shares.
This makes their stake in Taro Pharmaceutical Indus total 650,089 shares worth $28 million.
On the other hand, there are companies that Krensavage Asset Management is getting rid of from its portfolio.
Krensavage Asset Management closed its position in Embecta Corp on 14th August 2024.
It sold the previously owned 1,070,810 shares for $23.1 million.
Paul Paolino also disclosed a decreased stake in Exelixis Inc by 0.2%.
This leaves the value of the investment at $37.7 million and 1,677,393 shares.
The two most similar investment funds to Krensavage Asset Management are Palisades Hudson Asset Management, L.P. and Nomura Asset Management U.k. They manage $218 million and $218 million respectively.
Krensavage Asset Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 78.7% of
the total portfolio value.
The fund focuses on investments in the United States as
53.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
31% of the total holdings value.
On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $19.8 billion.
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Exelixis Inc |
21.39%
1,677,393
|
$37,691,000 | 17.31% |
| United Therapeutics Corp |
41.69%
118,208
|
$37,655,000 | 17.29% |
| Biogen Inc |
30.00%
123,785
|
$28,696,000 | 13.18% |
| Taro Pharmaceutical Indus |
1.09%
650,089
|
$27,954,000 | 12.83% |
| Embecta Corp |
Closed
1,070,810
|
$23,129,000 | |
| Cardinal Health, Inc. |
38.47%
217,656
|
$21,400,000 | 9.83% |
| Enanta Pharmaceuticals Inc |
81.98%
1,251,338
|
$16,230,000 | 7.45% |
| Jazz Pharmaceuticals plc |
Opened
109,076
|
$11,642,000 | 5.35% |
| Biontech Se-adr |
Opened
132,293
|
$10,631,000 | 4.88% |
| Regeneron Pharmaceuticals, Inc. |
86.73%
7,853
|
$8,254,000 | 3.79% |
| Sanofi-adr |
Opened
153,832
|
$7,464,000 | 3.43% |
| Alkermes plc |
76.66%
257,554
|
$6,207,000 | 2.85% |
| Vanda Pharmaceuticals Inc |
82.44%
662,166
|
$3,741,000 | 1.72% |
| Kodiak Sciences Inc |
Closed
344,634
|
$2,378,000 | |
| Eagle Pharmaceuticals Inc |
Closed
113,437
|
$2,205,000 | |
| Mural Oncology Plc |
Opened
75,057
|
$236,000 | 0.11% |
| No transactions found | |||
| Showing first 500 out of 16 holdings | |||